Last Updated: 22-01-2021 11:41
The following key policy questions are discussed regarding chromate exposure:
- What is the level of exposure occupationally relevant to Cr(VI) in the EU population?
- What are the groups of risk?
- Has the regulation under REACH had the favorable impact like a reduction of GM/median concentrations?
- What are the current HBM methods for Cr(VI)?
- Which are the appropriate biomarkers for Cr(VI)?